TPG Biotech follows on investing in drug development company Trevi Therapeutics, which shares its name with the famous Trevi fountain in Rome (pictured), after backing the company's seed round.
TPG Biotech, the life science venture unit of private equity firm TPG, has invested in a $10m round raised by Trevi Therapeutics, a US-based drug development company which treats itch condition, uremic pruritus.
TPG Biotech invested in the series A round having also backed the company’s seed round. Trevi also previously received funding from angel investors. New Haven, Connecticut-based Trevi was founded in 2011, and it is developing its drug T111 for the severe chronic itching condition.
Trevi says there…
